Loading...

Alkermes

DB:8AK
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8AK
DB
$5B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
8AK Share Price and Events
7 Day Returns
-7.6%
DB:8AK
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-23.7%
DB:8AK
-9.2%
DE Biotechs
-6.7%
DE Market
8AK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alkermes (8AK) -7.6% -5.8% -2% -23.7% -20.1% -14.5%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 8AK underperformed the Biotechs industry which returned -9.2% over the past year.
  • 8AK underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
8AK
Industry
5yr Volatility vs Market

8AK Value

 Is Alkermes undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Alkermes to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Alkermes.

DB:8AK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:8AK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 7.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 12.5%) (5.3%))
1.351
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.35
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.351 * 7.14%)
9.87%

Discounted Cash Flow Calculation for DB:8AK using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Alkermes is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:8AK DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.87%)
2019 -5.14 Analyst x4 -4.68
2020 6.30 Analyst x5 5.22
2021 168.67 Analyst x4 127.16
2022 389.32 Analyst x3 267.15
2023 580.95 Analyst x3 362.82
2024 742.08 Est @ 27.74% 421.81
2025 886.67 Est @ 19.48% 458.71
2026 1,008.21 Est @ 13.71% 474.72
2027 1,105.64 Est @ 9.66% 473.82
2028 1,181.19 Est @ 6.83% 460.71
Present value of next 10 years cash flows $3,047.42
DB:8AK DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,181.19 × (1 + 0.23%) ÷ (9.87% – 0.23%)
$12,275.07
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,275.07 ÷ (1 + 9.87%)10
$4,787.74
DB:8AK Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,047.42 + $4,787.74
$7,835.16
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,835.16 / 156.88
$49.94
DB:8AK Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:8AK represents 0.86361x of NasdaqGS:ALKS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86361x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 49.94 x 0.86361
€43.13
Value per share (EUR) From above. €43.13
Current discount Discount to share price of €29.00
= -1 x (€29.00 - €43.13) / €43.13
32.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Alkermes is available for.
Intrinsic value
33%
Share price is €29 vs Future cash flow value of €43.13
Current Discount Checks
For Alkermes to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Alkermes's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Alkermes's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alkermes's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alkermes's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8AK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.90
NasdaqGS:ALKS Share Price ** NasdaqGS (2019-04-18) in USD $33.58
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alkermes.

DB:8AK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ALKS Share Price ÷ EPS (both in USD)

= 33.58 ÷ -0.90

-37.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alkermes is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Alkermes is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Alkermes's expected growth come at a high price?
Raw Data
DB:8AK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -37.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
55.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alkermes, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alkermes's assets?
Raw Data
DB:8AK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.52
NasdaqGS:ALKS Share Price * NasdaqGS (2019-04-18) in USD $33.58
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:8AK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ALKS Share Price ÷ Book Value per Share (both in USD)

= 33.58 ÷ 7.52

4.47x

* Primary Listing of Alkermes.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alkermes is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Alkermes's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alkermes has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

8AK Future Performance

 How is Alkermes expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alkermes expected to grow at an attractive rate?
  • Alkermes's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Alkermes's earnings growth is expected to exceed the Germany market average.
  • Alkermes's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8AK Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8AK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 55.7%
DB:8AK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 8.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8AK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8AK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,692 593 363 7
2022-12-31 1,509 365 223 7
2021-12-31 1,304 228 0 9
2020-12-31 1,158 155 -214 12
2019-12-31 1,153 48 -148 12
DB:8AK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,094 99 -139
2018-09-30 1,054 75 -139
2018-06-30 1,023 61 -141
2018-03-31 937 6 -152
2017-12-31 903 19 -158
2017-09-30 842 -9 -169
2017-06-30 804 -14 -196
2017-03-31 781 -20 -200
2016-12-31 746 -64 -208
2016-09-30 695 -69 -257
2016-06-30 668 -113 -275
2016-03-31 624 -100 -274

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alkermes's earnings are expected to grow significantly at over 20% yearly.
  • Alkermes's revenue is expected to grow by 8.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8AK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Alkermes Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8AK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.56 3.74 1.68 4.00
2022-12-31 1.34 2.50 0.73 5.00
2021-12-31 0.08 1.05 -0.55 6.00
2020-12-31 -1.19 -0.41 -2.05 6.00
2019-12-31 -0.93 -0.77 -1.04 9.00
DB:8AK Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.90
2018-09-30 -0.90
2018-06-30 -0.92
2018-03-31 -0.99
2017-12-31 -1.03
2017-09-30 -1.11
2017-06-30 -1.28
2017-03-31 -1.32
2016-12-31 -1.38
2016-09-30 -1.70
2016-06-30 -1.83
2016-03-31 -1.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Alkermes is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Alkermes's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alkermes has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

8AK Past Performance

  How has Alkermes performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alkermes's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alkermes does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Alkermes's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alkermes's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alkermes's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alkermes Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8AK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,094.27 -139.31 537.41 414.41
2018-09-30 1,053.88 -139.39 506.98 409.62
2018-06-30 1,022.55 -141.22 477.33 413.27
2018-03-31 936.75 -151.57 447.53 406.10
2017-12-31 903.37 -157.95 431.18 403.29
2017-09-30 841.52 -169.30 417.13 388.72
2017-06-30 804.37 -195.71 408.44 383.96
2017-03-31 780.70 -199.90 395.41 382.01
2016-12-31 745.69 -208.44 383.13 378.15
2016-09-30 695.28 -256.69 373.26 382.41
2016-06-30 667.69 -275.01 371.51 375.62
2016-03-31 623.90 -273.93 346.63 366.80
2015-12-31 628.34 -227.16 319.66 336.30
2015-09-30 640.40 -127.27 286.79 317.25
2015-06-30 647.74 -86.21 248.88 303.26
2015-03-31 649.79 -36.36 227.91 282.68
2014-12-31 618.79 -30.06 206.81 265.14
2014-09-30 598.11 -42.50 200.67 234.93
2014-06-30 577.92 -10.30 188.64 202.21
2014-03-31 563.12 -6.71 167.51 171.87
2013-12-31 596.33 20.65 162.34 152.83
2013-09-30 577.76 18.83 143.93 139.53
2013-06-30 561.94 9.88 135.01 129.57
2013-03-31 575.55 24.98 130.76 135.01
2012-12-31 542.60 -41.37 100.61 145.20
2012-09-30 532.33 -72.46 109.61 150.98
2012-06-30 480.33 -78.01 113.12 145.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alkermes has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alkermes has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alkermes improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alkermes's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alkermes has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

8AK Health

 How is Alkermes's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alkermes's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alkermes is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alkermes's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alkermes's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alkermes Company Filings, last reported 3 months ago.

DB:8AK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,171.29 279.31 539.30
2018-09-30 1,150.72 279.85 467.09
2018-06-30 1,158.16 280.39 433.51
2018-03-31 1,155.89 280.93 404.56
2017-12-31 1,202.81 281.44 433.50
2017-09-30 1,187.28 281.99 450.10
2017-06-30 1,202.09 282.55 475.11
2017-03-31 1,216.70 283.11 476.42
2016-12-31 1,209.48 283.67 497.23
2016-09-30 1,209.69 285.58 549.46
2016-06-30 1,243.53 347.03 655.98
2016-03-31 1,265.08 348.49 625.39
2015-12-31 1,314.28 349.94 534.78
2015-09-30 1,366.81 353.22 771.76
2015-06-30 1,398.99 354.81 776.77
2015-03-31 1,420.42 356.39 747.46
2014-12-31 1,396.84 355.76 631.17
2014-09-30 1,333.59 359.55 572.57
2014-06-30 1,351.83 361.22 638.49
2014-03-31 1,339.50 362.90 552.27
2013-12-31 1,065.19 364.57 362.23
2013-09-30 1,016.98 366.24 339.43
2013-06-30 981.94 367.98 228.54
2013-03-31 952.37 369.55 221.35
2012-12-31 919.94 369.73 209.30
2012-09-30 885.01 371.22 199.45
2012-06-30 882.49 444.78 164.37
  • Alkermes's level of debt (23.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (34.1% vs 23.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Alkermes has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Alkermes has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -77.1% per year.
X
Financial health checks
We assess Alkermes's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alkermes has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

8AK Dividends

 What is Alkermes's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alkermes dividends. Estimated to be 0% next year.
If you bought €2,000 of Alkermes shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alkermes's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alkermes's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8AK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8AK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 4.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alkermes has not reported any payouts.
  • Unable to verify if Alkermes's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alkermes's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alkermes has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Alkermes's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Alkermes's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alkermes afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alkermes has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

8AK Management

 What is the CEO of Alkermes's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Pops
COMPENSATION $9,380,493
AGE 56
TENURE AS CEO 7.6 years
CEO Bio

Mr. Richard F. Pops has been the Chief Executive Officer of Alkermes PLC since September 2011. Mr. Pops was the Founder of Genomics Collaborative, Inc. He was a Co-founder of Sirtris Pharmaceuticals, Inc. He served as Chief Executive Officer of Alkermes, Inc. from September 2009 to September 2011 and previously served as its Chief Executive Officer from February 1991 to April 2007. He served as the President of Alkermes, Inc. from September 11, 2009 to September 16, 2011. He was employed by PaineWebber Development Corporation as a Vice President. He has been the Chairman at Alkermes PLC since September 16, 2011. He served as Chairman of Alkermes, Inc. from April 01, 2007 to September 2011 and served as its Director from February 1991 to September 2011. He has been a Director at Acceleron Pharma, Inc. since June 2004. Mr. Pops has been an Independent Director of Epizyme, Inc. since September 2008 and of Neurocrine Biosciences Inc. since April 16, 1998. He has been Member of Value and Coverage Advisory Council at FasterCures/The Center for Accelerating Medical Solutions since January 2015. He serves a Director at New England Healthcare Institute (NEHI). He serves as a Director At Large at Biotechnology Innovation Organization. He serves as a Member of Advisory Board at Polaris Partners. Mr. Pops serves as a Trustee of Fessenden School, The. He serves on board of The Biotechnology Industry Organization (BIO); the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Health Council. He served as a Lead Director at Acceleron Pharma, Inc. since October 2007. He served as a Member of Harvard Medical School Board of Fellows from 2002 to June 2012. He served as a Member of Advisory Board at Polaris Venture Partners, Inc. He served as Director of Sirtris Pharmaceuticals, Inc from 2004 to 2008 and CombinatoRx, Inc. from 2001 to 2009. He served as a Director of Expressive Constructs, Inc. He served as Director of Genomics Collaborative, Inc. He served as a Director of Zalicus Inc. from October 2001 to December 2009 and Reliant Pharmaceuticals, Inc. since June 2006. He served as a Director at The Massachusetts Biotechnology Council. He served as Chair for the Harvard Medical School Advisory Council for Biological Chemistry & Molecular Pharmacology (BCMP). Mr. Pops received a B.A. in Economics from Stanford University in 1983.

CEO Compensation
  • Richard's compensation has been consistent with company performance over the past year.
  • Richard's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alkermes management team in years:

5.8
Average Tenure
51
Average Age
  • The average tenure for the Alkermes management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Richard Pops

TITLE
Chairman & CEO
COMPENSATION
$9M
AGE
56
TENURE
7.6 yrs

Floyd Bloom

TITLE
Co-Founder & Director
COMPENSATION
$462K
AGE
81

Jim Frates

TITLE
Senior VP & CFO
COMPENSATION
$3M
AGE
51
TENURE
7.6 yrs

Jim Robinson

TITLE
President & COO
AGE
48
TENURE
1.1 yrs

Iain Brown

TITLE
Senior VP of Finance & Chief Accounting Officer
AGE
49
TENURE
3.9 yrs

Sandy Coombs

TITLE
Co-Head of Investor Relations

Eva Stroynowski

TITLE
Co-Head of Investor Relations

David Gaffin

TITLE
Senior VP
AGE
46
TENURE
2.9 yrs

Mike Landine

TITLE
Senior VP of Corporate Development & Chief Risk Officer
COMPENSATION
$1M
AGE
64
TENURE
7.6 yrs

Madeline Coffin

TITLE
Senior Vice President of Human Resources
Board of Directors Tenure

Average tenure and age of the Alkermes board of directors in years:

7.6
Average Tenure
65
Average Age
  • The tenure for the Alkermes board of directors is about average.
Board of Directors

Richard Pops

TITLE
Chairman & CEO
COMPENSATION
$9M
AGE
56
TENURE
7.6 yrs

Floyd Bloom

TITLE
Co-Founder & Director
COMPENSATION
$462K
AGE
81
TENURE
7.6 yrs

Paul Mitchell

TITLE
Lead Independent Director
COMPENSATION
$487K
AGE
66
TENURE
6.7 yrs

David Anstice

TITLE
Independent Director
COMPENSATION
$472K
AGE
70
TENURE
7.6 yrs

Wendy Dixon

TITLE
Director
COMPENSATION
$462K
AGE
63
TENURE
7.6 yrs

Bob Breyer

TITLE
Director
COMPENSATION
$470K
AGE
74
TENURE
7.6 yrs

Shane Cooke

TITLE
Director
COMPENSATION
$4M
AGE
56
TENURE
1.1 yrs

Nancy Wysenski

TITLE
Director
COMPENSATION
$465K
AGE
60
TENURE
5.9 yrs

Nancy Snyderman

TITLE
Director
COMPENSATION
$452K
AGE
65
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Alkermes insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 19 Buy Nancy Wysenski Individual 21. Feb 19 14. Mar 19 4,302 €29.28 €125,942
13. Dec 18 Sell David Anstice Individual 12. Dec 18 12. Dec 18 -3,787 €31.62 €-118,771
X
Management checks
We assess Alkermes's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alkermes has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

8AK News

Simply Wall St News

8AK Company Info

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company’s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Details
Name: Alkermes plc
8AK
Exchange: DB
Founded: 1987
$4,686,512,225
156,882,423
Website: http://www.alkermes.com
Address: Alkermes plc
Connaught House,
1 Burlington Road,
Dublin,
Co. Dublin, 4,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ALKS Common Shares Nasdaq Global Select US USD 16. Jul 1991
DB 8AK Common Shares Deutsche Boerse AG DE EUR 16. Jul 1991
Number of employees
Current staff
Staff numbers
2,300
Alkermes employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:22
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.